Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41780 | 0.62 | — | — | |
| SCHEMBL2406 | 0.62 | ALDH1A1 (0.30) | ALDH1A1TSHRHSD17B10 | |
| Water SCHEMBL28911661 | 0.59 | — | — | |
| SCHEMBL27910347 | 0.59 | — | — | |
| SCHEMBL28088600 | 0.59 | — | — | |
| SCHEMBL5473985 | 0.59 | — | — | |
| SCHEMBL28558299 | 0.59 | — | — | |
| Bromide SCHEMBL20500171 | 0.59 | — | — | |
| Iodide SCHEMBL20500202 | 0.59 | — | — | |
| Hydrogen Sulfide SCHEMBL27883970 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186825-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2018-07-05 | — | — | US | claimed |
| US-9908914-B2 | Methods of preparing substituted nucleoside analogs | ALIOS BIOPHARMA, INC. (US) | 2018-03-06 | — | — | US | claimed |
| EP-3212657-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | Alios Biopharma, Inc. (US) | 2017-09-06 | — | — | EP | claimed |
| WO-2016069489-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2016-05-06 | — | — | WO | claimed |
| US-20160115190-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2016-04-28 | — | — | US | claimed |
| CN-118076360-A | Compositions and methods for targeted RNA delivery | 维乎医疗有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117480008-A | Electro-grafted membranes for DNA synthesis | 金斯瑞美国有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117222647-A | Universal linker reagents for DNA synthesis | 金斯瑞美国公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-115484932-A | Compositions and methods for targeted RNA delivery | 维乎医疗有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-107108681-B | Process for preparing substituted nucleoside analogues | 詹森生物制药有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-10059733-B2 | Gemcitabine analogs | NUCORION PHARMACEUTICALS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180186825-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3212657-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | Alios Biopharma, Inc. (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20170088573-A1 | GEMCITABINE ANALOGS | NUCORION PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | disclosed |
| EP-3119795-A1 | GEMCITABINE ANALOGS | NUCORION PHARMACEUTICALS, INC. (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2016069489-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160115190-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2016-04-28 | — | — | US | disclosed |
| WO-2015134334-A1 | GEMCITABINE ANALOGS | SUO ZUCAI (US) | 2015-09-11 | — | — | WO | disclosed |
| WO-2013072903-A1 | NITROIMIDAZOXADIAZOCINE COMPOUNDS | ITHEMBA PHARMACEUTICALS (PROPRIETARY) LIMITED (ZA) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013068917-A1 | PROCESSES FOR THE PRODUCTION OF A LACTONE STATIN INTERMEDIATE BY ENZYMATIC OXIDATION | DR. REDDY'S LABORATORIES LIMITED (IN) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059733-B2 | Gemcitabine analogs | GMNN, RNASE1, TGM3 | ALDH1A1 2007/4885TSHR 3079/4885HSD17B10 4079/4885 |
| US-20160115190-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | PNP, NUDT1, ADAR | ALDH1A1 1413/4885TSHR 3862/4885HSD17B10 2784/4885 |
| US-20180186825-A1 | METHODS OF PREPARING SUBSTITUTED NUCLEOSIDE ANALOGS | PNP, NUDT1, ADAR | ALDH1A1 1413/4885TSHR 3862/4885HSD17B10 2784/4885 |
| US-20170088573-A1 | GEMCITABINE ANALOGS | GMNN, RNASE1, TGM3 | ALDH1A1 2007/4885TSHR 3079/4885HSD17B10 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.